In a new wave of crackdowns on compliance in the pharma sector in China, 10 medical meetings have been cancelled in short order, while sector-wide stock prices have plunged and 100 hospital officials placed under investigation, shocking the industry.

Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.

With the world' s second largest concentration of HIV patients (after Africa), Southeast Asia is a booming market for AIDS products. Government initiatives to prevent and combat the spread of this virus present opportunities for Western companies in both diagnostic and therapeutic products.